Overview

Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis

Status:
Terminated

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

The aim of the study is to assess the efficacy (superiority testing) of gusperimus compared to conventional treatment in patients with a relapse of Wegener Granulomatosis with or without ongoing steroids, and/or immunosuppressive therapy. Further, to evaluate the safety and quality of life of gusperimus treatment compared to standard treatment in patients with relapse of Wegener Granulomatosis receiving glucocorticoids.

Phase:

Phase 3

Details

Lead Sponsor:

Nordic Pharma SAS

Treatments:

Azathioprine
Cyclophosphamide
Glucocorticoids
Gusperimus
Methotrexate